Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tree mushroom drink calm inflammatory bowel disease?

NCT ID NCT07766733

Disease control Sponsor: Good Feeling Products GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This pilot study is testing whether a dietary supplement made from the tinder fungus can safely ease gut symptoms in adults with mild-to-moderate ulcerative colitis or Crohn's disease. Participants will drink the supplement and be monitored for changes in symptoms, inflammation markers, and endoscopic findings. The goal is to see if this natural product might offer a new way to help manage these chronic inflammatory bowel conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement made from the tinder fungus (Fomes fomentarius), taken as a drink
What this could lead to
If it works, this supplement could offer a natural, well-tolerated option to help manage gut symptoms in people with mild-to-moderate ulcerative colitis or Crohn's disease.
What could go wrong
This is a small, early pilot study, so results may not apply broadly. The supplement's safety and effectiveness are still unproven, and it is not a replacement for standard medical care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Nov 2023

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 - 64 * BMI 18.5 - 32.0 kg/m² * Mild-to-moderate UC or colonic/ileal CD * At least one prior episode of active disease Exclusion Criteria: * Extensive colonic resection or subtotal or total colectomy * Currently required or anticipated surgical intervention during the study * Any prior exposure to natalizumab, efalizumab, or rituximab * History or evidence of colonic mucosal dysplasia * Female patients who are lactating or have a positive pregnancy test * Any unstable or uncontrolled medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease (CD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease (CD) Ulcerative colitis (UC)

Contacts and locations

Locations

  • Centro Medico Teknon

    Barcelona, 08022, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.